

ASBMR Symposium

Bone-omics: Translating Genomic Discoveries into Clinical Applications

September 15, 2016

Georgia World Congress Center
Atlanta, Georgia

The logo for the ASBMR 2016 Annual Meeting. It features the text "ASBMR" in a bold, sans-serif font, followed by a registered trademark symbol (®). To the right of "ASBMR" is a stylized white arch. To the right of the arch is the year "2016" in a large, bold, sans-serif font. Below "2016" is the text "Annual Meeting" in a smaller, sans-serif font. The entire logo is white and is positioned in the bottom right corner of the image, which has a dark red background with a faint, repeating pattern of DNA double helices and bone structures.

ASBMR® 2016
Annual Meeting

This meeting is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA) and the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health under Award Number R13AR070644. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

GENERAL MEETING INFORMATION

Registration

Registration desks will be open for new registrants in the Georgia World Congress Center in the Registration Hall, Main Entrance on **Thursday, September 15 from 7:00 am – 6:00 pm.**

Speaker Ready Room

Speakers must check into the Speaker Ready Room in advance of their presentation. At that time, speakers may review their slides. The Speaker Ready Room is located in Room A406 in the Georgia World Congress Center. The Speaker Ready Room will be open on **Thursday, September 15 from 7:00 am – 5:00 pm**

Organizing Committee

Douglas Kiel, MD, MPH
Fernando Rivadeneira, MD, PhD
Cheryl Ackert-Bicknell, PhD
Eric Orwoll, MD

Support

The American Society for Bone and Mineral Research (ASBMR) recognizes the generous support provided by:

LGC
UCB

CONTINUING MEDICAL EDUCATION



This activity has been planned and implemented by Creighton University Health Sciences Continuing Education (HSCE) and The American Society for Bone and Mineral Research (ASBMR) for the advancement of patient care. Creighton University Health Sciences Continuing Education is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

AMA PRA Statement

Creighton University Health Sciences Continuing Education designates this live activity for a maximum of 6 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity

AAPA accepts AMA category 1 credit for the PRA from organizations accredited by ACCME.

Online Evaluation to Receive CME

The online evaluation to receive CME will be available beginning Thursday, September 22. You will receive an email from ASBMR with instructions on how to claim credit.

Target Audience

This meeting will bring together national and international investigators currently working in the field of genomics as well as young and established investigators, industry scientists, NIH intramural scientists and program staff, clinicians, endocrinologists and basic and translational researchers.

Learning Objectives

Upon returning home from the meeting, participants should be able to:

1. Appraise the latest contributions of the field of genomics to the understanding of skeletal disease mechanisms, ranging from basic molecular biology to animal models and bidirectional translation to humans, particularly within the scope of precision medicine and targeted treatments.
2. Provide participants with an updated view of how new technological innovations and novel methodological approaches in the field of genomics offer the possibility to translate the new knowledge into palpable clinical applications.
3. Promote how medicine can be revolutionized by these novel approaches and is already evident in the area of therapeutics.

ASBMR Expectations of Authors and Presenters

Through ASBMR meetings, the Society promotes excellence in bone and mineral research. Toward that end, ASBMR expects that all authors and presenters affiliated with the ASBMR Symposium on Bone-omics: Translating Genomic Discoveries into Clinical Applications will provide informative and fully accurate content that reflects the highest level of scientific rigor and integrity.

ASBMR depends upon the honesty of the authors and presenters and relies on their assertions that they have had sufficient full access to the data and are convinced of its reliability.

Furthermore, ASBMR expects that:

- Authors and presenters will disclose any conflicts of interest, real or perceived.
- Authors of an abstract describing a study funded by an organization with a proprietary or financial interest must affirm that they had full access to all the data in the study. By so doing, they accept complete responsibility for the integrity of the data and the accuracy of the data analysis.
- The content of abstracts, presentations, slides and reference materials must remain the ultimate responsibility of the author(s) or faculty.
- The planning, content and execution of abstracts, speaker presentations, slides, abstracts and reference materials should be free from corporate influence, bias or control.
- All authors and presenters (invited and abstracts-based oral and poster presenters) should give a balanced view of therapeutic options by providing several treatment options, whenever possible, and by always citing the best available evidence.

Disclosure Policy

The ASBMR is committed to ensuring the balance, independence, objectivity and scientific rigor of all its individually sponsored or industry-supported educational activities. Accordingly, the ASBMR adheres to the requirement set by ACCME that audiences at jointly-sponsored educational programs be informed of a presenter's (speaker, faculty, author, or planner) academic and professional affiliations, and the disclosure of the existence of any significant financial interest or other relationship a presenter or their spouse has with any proprietary entity over the past 12 months producing, marketing, re-selling or distributing health care goods or services, consumed by, or used on patients, with the exemption of non-profit or government organizations and non-health care related companies. When an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose, is discussed during the presentation, it is required that presenters disclose that the product is not labeled for the use under discussion or that the product is still investigational. This policy allows the listener/attendee to be fully knowledgeable in evaluating the information being presented. The On-Site Program book will note those speakers who have disclosed relationships, including the nature of the relationship and the associated commercial entity.

Disclosure should include any affiliation that may bias one's presentation or which, if known, could give the perception of bias. This includes relevant financial affiliations of a spouse or partner. If an affiliation exists that could represent or be perceived to represent a conflict of interest, this must be reported in the abstract submission program by listing the name of the commercial entity and selecting the potential conflict(s) by clicking in the box next to the relationship type. Disclosures will be printed in the program materials. These situations may include, but are not limited to: (1) Grant/Research Support; (2) Consultant; (3) Speakers' Bureau; (4) Major Stock Shareholder; (5) Other Financial or Material Support.

Copyright

Abstracts submitted to the ASBMR 2016 Annual Meeting and presented at the ASBMR Symposium on Bone-omics: Translating Genomic Discoveries into Clinical Applications are copyrighted by the American Society for Bone and Mineral Research. Reproduction, distribution, or transmission of the abstracts in whole or in part, by

electronic, mechanical, or other means, or intended use, is prohibited without the express written permission of the American Society for Bone and Mineral Research.

Disclaimer

All authored abstracts, findings, conclusions, recommendations, or oral presentations are those of the author(s) and do not reflect the views of the ASBMR or imply any endorsement. No responsibility is assumed, and responsibility is hereby disclaimed, by the American Society for Bone and Mineral Research for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of methods, products, instructions, or ideas presented in the materials herein (2016 Abstracts). Independent verification of diagnosis and drug dosages should be made. Discussions, views, and recommendations as to medical procedures, choice of drugs, and drug dosages are the responsibility of the authors.

Audio and Video Recording

ASBMR expects that attendees respect each presenter's willingness to provide free exchange of scientific information without the abridgement of his or her rights or privacy and without the unauthorized copying and use of the scientific data shared during his or her presentation. In addition, ASBMR expects that attendees will respect exhibitors' desires not to have their products or booths photographed or video-recorded.

The use of cameras, audio-recording devices, and video-recording equipment is strictly prohibited within all Scientific Sessions, the Exhibit Halls, and Poster Sessions without the express written permission of both the ASBMR and the presenter/exhibitor. Unauthorized use of the recording equipment may result in the confiscation of the equipment or the individual may be asked to leave the session or Exhibit Hall. These rules are strictly enforced.

Meeting Evaluation

An online evaluation form for the ASBMR Symposium on Bone-omics: Translating Genomic Discoveries into Clinical Applications will be available on the ASBMR Website at www.asbmr2016.org after the meeting and sent to you via email. Your participation in this evaluation is extremely important to us. Please take a moment to complete the evaluation of this meeting to aid in planning future meetings. Thank you in advance for your feedback.

Use of ASBMR Name and Logo

ASBMR reserves the right to approve the use of its name in all materials disseminated to the press, public and professionals. The ASBMR name, meeting name, and meeting logo may not be used without permission. Use of the ASBMR logo is prohibited without the express written permission of the ASBMR Executive Director. All ASBMR corporate supporters and exhibitors should share their media outreach plans with the ASBMR before release.

No abstract presented at the ASBMR Symposium may be released to the press before its official presentation date and time. Press releases must be embargoed until one hour after the presentation.

Future ASBMR Annual Meeting Dates

ASBMR 2017 Annual Meeting

Colorado Convention Center, Denver, Colorado, USA
September 8 – 11, 2017

ASBMR 2018 Annual Meeting

Palais des Congrès de Montréal, Montreal, Quebec, Canada
September 28 – October 1, 2018

THURSDAY, SEPTEMBER 15, 2016

CONTINENTAL BREAKFAST

8:00 am – 9:00 am

Room A412

THE –OMICS REVOLUTION IN MOLECULAR MEDICINE

9:00 am – 10:30 am

Room A412

Co-Chairs:

Eric Orwoll, M.D., Ph.D., Oregon Health & Science University

Joan McGowan, Ph.D., National Institute of Arthritis, Musculoskeletal & Skin Disease

9:00 am 25 years Since the Human Genome Project: New Tools and Technologies to Lessen the Burden of Disease

Eric Boerwinkle, Ph.D., University of Texas Health Science Center

Disclosures: None

9:30 am Integrating –omics Platforms: A Glimpse into the Future of Clinical Practice

Nicholas J. Schork, Ph.D., J. Craig Venter Institute

Disclosures: None

10:00 am Integrating –omics and Phenomics: Elucidating Molecular Mechanisms Influencing Therapeutic Decision Making

Greg Gibson, Ph.D., Georgia Institute of Technology

Disclosures: None

BREAK AND POSTER VIEWING

10:45 am – 11:30 am

Room A411

MODEL CELLS AND ORGANISMS TO UNDERSTAND GENOME BIOLOGY

11:30 am – 1:00 pm

Room A412

Co-Chairs:

Cheryl Ackert-Bicknell, Ph.D., University of Rochester

Michael Econs, M.D., Indiana University School of Medicine

11:30 am Induced Pluripotent Stem Cells (iPSCs) for the Understanding of Human Musculoskeletal Disease

Pamela G. Robey, Ph.D., National Institute of Dental and Craniofacial Research

Disclosures: None

12:00 pm International Mouse Phenotyping Consortium: Past, Present and Future... Making Mouse Models for All Protein Coding Genes

Steve Brown, Ph.D., Medical Research Council Harwell, United Kingdom

Disclosures: None

12:30 pm Systems Biology: Gene and Networks Underlying the Molecular Basis of Musculoskeletal Disease

Charles Farber, Ph.D., University of Virginia

Disclosures: None

LUNCH AND POSTER VIEWING

1:00 pm – 2:00 pm

Room A411

BIG DATA AND NETWORKS

2:00 pm – 3:30 pm

Room A412

Co-Chairs:

Fernando Rivadeneira, M.D., Ph.D., Erasmus MC Rotterdam, The Netherlands

Lynda Bonewald, Ph.D., Indiana University School of Medicine

2:00 pm Model Cells, Organisms and Human Populations: BIG DATA in Musculoskeletal Research

André G. Uitterlinden, Ph.D., Erasmus Medical Center Rotterdam, The Netherlands

Disclosures: None

2:30 pm Translating Genetics into Therapeutics by Systematic Dissection of Regulatory Mechanisms

Manolis Kellis, Ph.D., Massachusetts Institute of Technology

Disclosures: None

3:00 pm Methods for Integrating Data to Uncover Genotype-phenotype Interactions

Marylyn D. Ritchie, Ph.D., Pennsylvania State University

Disclosures: Geisinger Health System and Regeneron Genetics Center, 1

BREAK

3:30 pm – 3:45 pm

Room A412

GENOMICS APPLIED IN THERAPEUTICS

3:45 pm – 5:15 pm

Room A412

Co-Chairs:

Emma Duncan, Ph.D., Royal Brisbane and Women's Hospital, Australia

Douglas Kiel, M.D., M.P.H., Hebrew SeniorLife, Harvard University

3:45 pm Promoters and Enhancers: DNA Regulatory Elements as Drug Targets

Matthew Maurano, Ph.D., New York University

Disclosures: None

4:15 pm Genomic Discoveries for the Development of New Medications

Matthew Nelson, M.D., Ph.D., Glaxo SmithKline

Disclosures: GlaxoSmithKline, 4, GlaxoSmithKline, 5

4:45 pm The Translational Landscape of Genomic Research: From Cells and Model Organisms to Human Treatments

Robert Plenge, M.D., Ph.D., Merck Sharp & Dohme

Disclosures: Merck, 5

CLOSING REMARKS

5:15 pm - 5:30 pm

Room A412



The American Society for
Bone and Mineral Research

American Society for Bone and Mineral Research

2025 M Street, NW, Suite 800

Washington, DC 20036-3309 USA

Tel: +1 (202) 367-1161 | Fax: +1 (202) 367-2161

Email: asbmr@asbmr.org | www.asbmr.org